(Day One Biopharmaceuticals) Shares of Day One Biopharmaceuticals rose more than 110% on Monday after announcing positive initial data for its neuro-oncology treatment.
Day One lauded positive initial data from the first 22 Response Assessment for Neural-Oncology evaluable patients.
The biopharma company said that the overall response rate was recorded at 64%, with a clinical benefit rate of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib.
Day One plans to start a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma. The company targets the first dosed patient in the third quarter of this year.
The company said that the topline results for the full FIREFLY-1 trial population are expected in the first quarter of 2023.
The company said that safety data showed the effects of monotherapy tovorafenib were well-tolerated in the first 25 patients.
DAWN: NASDAQ is up +111.03%.
